en · de · es · fr · pt
assay-notes.peptides1126.com › Guide › Background And Receptor Selectivity — Reference Sheet

Background And Receptor Selectivity — Reference Sheet

By Editorial Desk · published 2026-03-11 · last reviewed 2026-04-13 · Guide

If you have been reading about freeze-thaw and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2026-04-13. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Receptor Selectivity

Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.

Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.

Ipamorelin Background and Pharmacology

Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.

At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.

Ipamorelin at a glance

PropertyValueNotes
Molecular formulaC38H49N9O5Value for the free base
Molar mass711.9 g/molCalculated from the formula
AppearanceWhite to off-white powderTypical lyophilized form
Mechanism classGhrelin receptor agonistAlso described as a secretagogue
Half-lifeAbout 2 hoursReported for human circulation

Ipamorelin Background and Receptor Selectivity

Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.

Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.

Related pages on this site

Ipamorelin Background and Receptor Pharmacology

Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.

In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.

Handling Storage And Analytical Control

In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.

Research peptides such as ipamorelin are commonly supplied as lyophilized powder and characterized by analytical certificates. Reversed-phase high-performance liquid chromatography is used to estimate purity by ultraviolet absorbance, while mass spectrometry confirms molecular identity and detects sequence-related impurities. Counterion content, water content, and residual synthesis reagents can affect the reported mass balance. A certificate of analysis may list a purity percentage, but that number depends on the analytical method and the definition of impurity peaks. Independent verification is often recommended because research supply chains vary in quality control practices.

Background from the literature

==== Isobaric labeling ==== Isobaric mass tags (tandem mass tags) are tags that have identical mass and chemical properties that allow heavy and light isotopologues to co-elute together. All mass tags consist of a mass reporter that has a unique number of 13C substitutions, a mass normalizer that has a unique mass that balances the mass of the tag to make all the tags equal in mass and a reactive moiety that crosslinks to the peptides. These tags are designed to cleave at a specific linker region upon high-energy CID, yielding different-sized tags that are then quantitated by LC-MS/MS. Protein or peptide samples prepared from cells, tissues or biological fluids are labeled in parallel with the isobaric mass tags and combined for analysis. Protein quantitation is accomplished by comparing the intensities of the reporter ions in the MS/MS spectra. Three types of tandem mass tags are available with different reactivity: (1) reactive NHS ester which provides high-efficiency, amine-specific labeling (TMTduplex, TMTsixplex, TMT10plex and TMT11plex), (2) reactive iodacetyl function group which labels sulfhydryl-(-SH) groups (iodoTMT) and (3) reactive alkoxyamine functional group which provides covalent labeling of carbonyl-containing compounds (aminoxyTMT). A key benefit of isobaric labeling over other quantification techniques (e.g. SILAC, ICAT, Label-free) is the increased multiplex capabilities and thus increased throughput potential.

== Past predictions == In May 1998, George Kennan described the US Senate vote to expand NATO to include Poland, Hungary, and the Czech Republic as "the beginning of a new cold war", and predicted that "the Russians will gradually react quite adversely and it will affect their policies". In 2001, foreign policy and security experts James M. Lindsay and Ivo Daalder described counterterrorism as the "new Cold War". British journalist Edward Lucas wrote in February 2008 that a new cold war between Russia and the West had already begun.

==== Phase transitions ==== At a pressure of one atmosphere (atm), ice melts or water freezes (solidifies) at 0 °C (32 °F) and water boils or vapor condenses at 100 °C (212 °F). However, even below the boiling point, water can change to vapor at its surface by evaporation (vaporization throughout the liquid is known as boiling). Sublimation and deposition also occur on surfaces. For example, frost is deposited on cold surfaces while snowflakes form by deposition on an aerosol particle or ice nucleus. In the process of freeze-drying, a food is frozen and then stored at low pressure so the ice on its surface sublimates. The melting and boiling points depend on pressure. A good approximation for the rate of change of the melting temperature with pressure is given by the Clausius–Clapeyron relation:

=== Urinary tract infection === People with diabetes show an increased rate of urinary tract infection. The reason is that bladder dysfunction is more common in people with diabetes than in people without diabetes due to diabetes nephropathy. When present, nephropathy can cause a decrease in bladder sensation, which in turn can cause increased residual urine, a risk factor for urinary tract infections.

==== Grafting from ==== This limitation can be overcome by polymerizing directly on the surface. This process is referred to as grafting from, or surface-initiated polymerization (SIP). As the name suggests, the initiator molecules must be immobilized on the solid surface. Like other polymerization methods, SIP can be tailored to follow radical, anionic, or cationic mechanisms and can be controlled utilizing reversible addition transfer polymerization (RAFT), atom transfer radical polymerization (ATRP), or nitroxide-mediated techniques. A controlled polymerization allows for the formation of stretched conformation polymer structures that maximize grafting density and thus biocidal efficiency. This process also allows for high density grafting of high molecular weight polymer which further improves efficacy.

Sources: en.wikipedia.org

Further detail

=== War in Yemen (2014–present) === Yemen was riven in 2015, with the Houthis establishing a new government in Sanaa and Hadi retreating with his supporters to Aden, and later Saudi Arabia. The Arab League, led by the Saudis, began a bombing campaign and mobilization of various armed forces in the region for a possible invasion.

== Genes == In humans, the gene for the alpha subunit is located at cytogenetic location 6q14.3. It is expressed in two cell types, most notably the basophils of the anterior pituitary. The gene for the FSH beta subunit is located on chromosome 11p13, and is expressed in gonadotropes of the pituitary cells, controlled by GnRH, inhibited by inhibin, and enhanced by activin.

The 5-HT2C receptors are G protein–coupled receptors that are coupled to phospholipase C (PLC) via Gαq, phospholipase A2 (PLA2), and possibly Gα13. PLC metabolizes phosphatidylinositol 4,5-bisphosphate into inositol 1,4,5-triphosphate (IP3). IP3 regulates cellular Ca2+ flux by binding to IP3 receptors, inducing Ca2+ release. In addition, the activation of PLA2 also results in recruitment of a RhoA/PLD pathway through RhoA, an enzyme that regulates a wide spectrum of cellular functions through PLD (phospholipase D) target protein. The 5-HT2C receptors can also stimulate the extracellular signal-regulated kinase (ERK) pathway which is activated by neurotrophins and other neuroactive chemicals. Production of these chemicals effects neuronal differentiation, survival, regeneration, and structural and functional plasticity. Early studies of the ERK pathway showed that mood stabilizers for the treatment of manic-depressive illness stimulated the pathway. This led to the understanding that stimulation of the 5-HT2C receptors could regulate manic-depressive conditions in a manner similar to mood stabilizers. 5-HT2C receptors are located only within the CNS, where they can be found in several locations. The highest density of receptor expression is within the choroid plexus. Other brain locations include the nucleus of the solitary tract, dorsomedial hypothalamus, paraventricular hypothalamic nucleus and the amygdala, all of which are associated with regulation of food intake.

However, it was found that the timers controlling the broadcasts could drift and the broadcasts from one station would begin to be seen at others, a phenomenon known as "running rabbits". To avoid this, power from the National Grid was used to provide a convenient phase-locked 50 Hz signal that was available across the entire nation. Each CH station was equipped with a phase-shifting transformer that triggered it at a different point on the grid waveform. The output of the transformer was fed to a Dippy oscillator that produced sharp pulses at 25 Hz, phase-locked to the output from the transformer. The locking was "soft", so short-term variations in the phase or frequency of the grid were filtered out. During times of strong ionospheric reflection, especially at night, it was possible that the receiver would see reflections from the ground after one reflection. To address this problem, the system was later provided with a second pulse repetition frequency at 12.5 pps, which meant that a reflection would have to be from further than 6,000 miles (9,700 km) away before it would be seen during the next reception period.

Locals are called "Branches," regional groups are called "Districts," and national convention meets quadrennially. "Supreme Office" reported to be at 9 Seventh Street, New York in 1923. Reported to be in Brooklyn in the 1970s. Now at 399 Conklin Street - Suite 310 Farmingdale. Two Chicago-based German groups have merged into the WBF - the Mutual Benefit Aid Society and American Fraternal Insurance Society founded by Volga Germans. Two Jewish groups have merged into the WBF, the Free Sons of Israel in 2001 and the Workmen’s Circle in 2004. Among its activities were providing scholarships, donating to charities, and operating a convalescent home, summer camp, and home for the aged. It also offers "usual line of fraternal insurance and benevolence for its members" Had 384 lodges and 53,139 benefit members in 1923, 53,000 in 1965, 35,000 on December 31, 1978 and 15,000 in 1995.

Sources: en.wikipedia.org

Frequently asked questions

Is ipamorelin an approved medicine?

It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.

Which receptor does it target?

It binds the ghrelin receptor, known as the growth hormone secretagogue receptor type 1a. Activation of that receptor triggers signaling that leads to growth hormone release. Selectivity for growth hormone over cortisol and prolactin is the property most often cited for this compound.

What is the reported half-life?

Published estimates place the circulating half-life at roughly two hours in humans. Clearance involves peptidase activity and renal handling. Because the peptide is short-lived, release patterns after administration are usually described as pulsatile rather than sustained.

What type of molecule is ipamorelin?

It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.

Network